ReviewThe Lancet regional health. Europe2023
EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data: a Delphi approach.
Review in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Mind the governance gap: a one health scoping review of national AMR performance indicators.npj antimicrobials and resistance · 2026Article
- China's nationwide antimicrobial resistance surveillance networks: a systematic analysis from One Health perspective.The Lancet regional health. Western Pacific · 2026Review
- Challenges and potential opportunities for improving One Health surveillance in low-resource settings: Insights from rabies surveillance in Malawi.One health outlook · 2026Article
- Toward standardized environmental detection of antibiotics and ARGs for regulatory interpretation and concern tiering.Frontiers in microbiology · 2026Review
- Nanopore sequencing in suitcase lab enables improved detection ofFrontiers in microbiology · 2026Article
- Antimicrobial Consumption and Utilisation in Zambia: Results from the Analysis of National Data for the Human and Animal Health Sectors.Antibiotics (Basel, Switzerland) · 2025Article
- Sources and Transmission Routes of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Measuring hospital antibiotic consumption in EU/EEA countries: comparison of different metrics, 2017 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Antimicrobial Resistance Surveillance: Data Harmonisation and Data Selection within Secondary Data Use.Antibiotics (Basel, Switzerland) · 2024Article
- Surveillance of Antimicrobial Resistance in the ECOWAS Region: Setting the Scene for Critical Interventions Needed.Antibiotics (Basel, Switzerland) · 2024Review
- Article
- Antibiotic quality and use practices amongst dairy farmers and drug retailers in central Kenyan highlands.Scientific reports · 2023Article
- Current Uses and Future Perspectives of Genomic Technologies in Clinical Microbiology.Antibiotics (Basel, Switzerland) · 2023Review
- Towards One Health surveillance of antibiotic resistance: characterisation and mapping of existing programmes in humans, animals, food and the environment in France, 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Review
- Network meta-analysis of antibiotic resistance patterns in gram-negative bacterial infections: a comparative study of carbapenems, fluoroquinolones, and aminoglycosides.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strategic and standardised approaches to analysis and reporting of surveillance data are essential to inform antimicrobial resistance (AMR) mitigation measures, including antibiotic policies. Targeted guidance on linking full-scale AMR and antimicrobial consumption (AMC)/antimicrobial residues (AR) surveillance data from the human, animal, and environmental sectors is currently needed. This paper describes the initiative whereby a multidisciplinary panel of experts (56 from 20 countries-52 high income, 4 upper middle or lower income), representing all three sectors, elaborated proposals for structuring and reporting full-scale AMR and AMC/AR surveillance data across the three sectors. An evidence-supported, modified Delphi approach was adopted to reach consensus among the experts for dissemination frequency, language, and overall structure of reporting; core elements and metrics for AMC/AR data; core elements and metrics for AMR data. The recommendations can support multisectoral national and regional plans on antimicrobials policy to reduce resistance rates applying a One Health approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.